Atara Biotherapeutics Inc. (ATRA) CEO Isaac E. Ciechanover Sells 4,800 Shares
Atara Biotherapeutics Inc. (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 4,800 shares of the company’s stock in a transaction dated Friday, October 14th. The shares were sold at an average price of $15.96, for a total value of $76,608.00. Following the transaction, the chief executive officer now directly owns 549,136 shares in the company, valued at $8,764,210.56. The sale was disclosed in a filing with the SEC, which is available through this link.
Atara Biotherapeutics Inc. (NASDAQ:ATRA) traded up 0.62% during mid-day trading on Monday, reaching $16.15. The company had a trading volume of 183,418 shares. The company’s market capitalization is $465.30 million. The firm’s 50 day moving average price is $19.63 and its 200-day moving average price is $20.24. Atara Biotherapeutics Inc. has a 12 month low of $13.31 and a 12 month high of $40.80.
Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Monday, August 8th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.61) by $0.05. Equities research analysts anticipate that Atara Biotherapeutics Inc. will post ($2.85) earnings per share for the current year.
A number of research analysts have recently weighed in on ATRA shares. JMP Securities reissued a “buy” rating on shares of Atara Biotherapeutics in a report on Saturday, July 9th. Citigroup Inc. increased their price objective on Atara Biotherapeutics from $8.00 to $10.00 and gave the company a “sell” rating in a report on Friday, August 19th. Zacks Investment Research lowered Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Thursday, September 22nd. Jefferies Group reissued a “buy” rating and issued a $25.00 price objective on shares of Atara Biotherapeutics in a report on Tuesday, August 9th. Finally, Goldman Sachs Group Inc. lowered Atara Biotherapeutics from a “neutral” rating to a “sell” rating and cut their price objective for the company from $23.00 to $16.00 in a report on Thursday, September 15th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $26.14.
Hedge funds have recently made changes to their positions in the company. Barclays PLC increased its stake in shares of Atara Biotherapeutics by 2,266.0% in the second quarter. Barclays PLC now owns 4,803 shares of the company’s stock worth $108,000 after buying an additional 4,600 shares during the period. BlackRock Inc. increased its stake in shares of Atara Biotherapeutics by 464.3% in the second quarter. BlackRock Inc. now owns 6,100 shares of the company’s stock worth $137,000 after buying an additional 5,019 shares during the period. PNC Financial Services Group Inc. increased its stake in shares of Atara Biotherapeutics by 6,736.5% in the second quarter. PNC Financial Services Group Inc. now owns 6,563 shares of the company’s stock worth $148,000 after buying an additional 6,467 shares during the period. Creative Planning acquired a new stake in shares of Atara Biotherapeutics during the third quarter worth about $213,000. Finally, Franklin Street Advisors Inc. NC acquired a new stake in shares of Atara Biotherapeutics during the third quarter worth about $214,000. 75.58% of the stock is owned by institutional investors.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.
Receive News & Stock Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.